GlassScriptPhysician profile
Arthur G Pacia
NPI 1225053846
$13,868.16
in general payments reported to CMS, 2019-2025
32 companies · $2,088 in 2025
The $2,088 reported for 2025 was more than what 77% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $569 · 2020: $978 · 2021: $2,154 · 2022: $2,700 · 2023: $3,140 · 2024: $2,240 · 2025: $2,088.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,309 · Education: $159.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,308.92 |
| Education | $158.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $4,441.95 | 2019-2025 | Fasenra, Farxiga, Breztri |
| Glaxosmithkline, LLC. | $3,571.18 | 2019-2025 | Arexvy, Nucala, Trelegy Ellipta |
| Amgen INC. | $1,060.11 | 2019-2025 | Repatha, Otezla, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $934.17 | 2020-2025 | Jardiance, Tradjenta, Ofev |
| Novo Nordisk INC | $759.23 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Janssen Pharmaceuticals, INC | $672.95 | 2019-2023 | Xarelto |
| Lilly USA, LLC | $481.20 | 2020-2025 | Zepbound, Mounjaro, Jardiance |
| Regeneron Healthcare Solutions, INC. | $317.79 | 2021-2025 | Dupixent |
| Genzyme Corporation | $273.97 | 2021-2025 | |
| Mylan Specialty L.P. | $226.99 | 2019-2024 | Yupelri |
| Sanofi-Aventis U.S. LLC | $211.70 | 2019-2024 | |
| Paratek Pharmaceuticals, INC. | $163.97 | 2023-2025 | Nuzyra, Xhance |
| Phathom Pharmaceuticals, INC. | $126.14 | 2024-2025 | Voquezna |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $96.65 | 2022-2024 | Xifaxan |
| Esperion Therapeutics, INC. | $78.32 | 2020-2024 | Nexletol |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $57.21 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $42.76 | 2020-2021 | |
| Abbvie INC. | $41.20 | 2021-2022 | |
| Hikma Pharmaceuticals USA | $40.74 | 2021-2023 | Mitigare, Ryaltris |
| Viatris Specialty LLC | $31.81 | 2025 | Yupelri |
| Pfizer INC. | $29.23 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $29.06 | 2024-2025 | Aralast |
| Kowa Pharmaceuticals America, INC. | $27.04 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $24.70 | 2020-2022 | |
| Currax Pharmaceuticals LLC | $24.58 | 2020-2021 | |
| Optinose US, INC. | $18.25 | 2024 | |
| Insmed, INC. | $17.34 | 2025 | Arikayce |
| Nabriva Therapeutics, Plc | $15.64 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $13.65 | 2019 | |
| Endo Pharmaceuticals INC. | $13.59 | 2020 | |
| Horizon Therapeutics Plc | $13.32 | 2022 | |
| Harmony Biosciences LLC | $11.72 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arthur Pacia listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.